| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8447900 | European Journal of Cancer | 2010 | 10 Pages |
Abstract
L19-IL2 can be safely and repeatedly administered at the RD of 22.5 Mio IU IL2 equivalent in advanced solid tumours. Preliminary evaluation suggests clinical activity of L19-IL2 in patients with mRCC.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Manfred Johannsen, Gianluca Spitaleri, Giuseppe Curigliano, Jan Roigas, Steffen Weikert, Carsten Kempkensteffen, Andreas Roemer, Christian Kloeters, Patrik Rogalla, Gabriele Pecher, Kurt Miller, Alexander Berndt, Hartwig Kosmehl, Eveline Trachsel,